Vimarsana
Biggest News Aggregation in the World

Page 14 - Sysmex Inostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sysmex Inostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sysmex Inostics Today - Breaking & Trending Today

Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients - Vimarsana News

Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients

Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients News provided by Share this article Share this article BALTIMORE, April 10, 2021 /PRNewswire/ -- Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster "Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer (NSCLC) patients" at the 112 th Annual Meeting of the American Association for Cancer Research on April 10, 2021...

Global Cancer Genomic Cancer Panel and Profiling (Germline/Somatic) Markets to 2025: Factors Driving Growth - Level of Care, Companion Dx, Immuno-oncology, Liability, Aging Population - Vimarsana News

Global Cancer Genomic Cancer Panel and Profiling (Germline/Somatic) Markets to 2025: Factors Driving Growth - Level of Care, Companion Dx, Immuno-oncology, Liability, Aging Population

3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay 4. Cancer Panels & Profiles Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform Wales to Routinely Screen Cancer Patients With Yourgene Elucigen...

Global Cancer Molecular Diagnostics Markets 2021-2025 - New Diagnostics Create New Markets - Vimarsana News

Global Cancer Molecular Diagnostics Markets 2021-2025 - New Diagnostics Create New Markets

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Working against this dynamic market are the f...

Global Next-Generation Sequencing (NGS) Market Segmentation, Parameters, Prospects 2021 And Forecast Research Report To 2027 – KSU - Vimarsana News

Global Next-Generation Sequencing (NGS) Market Segmentation, Parameters, Prospects 2021 And Forecast Research Report To 2027 – KSU

Global Next-Generation Sequencing (NGS) Market 27 “Global Next-Generation Sequencing (NGS) Market–Industry Trends and Forecast to 2028” New Research Report Added to Databridgemarketresearch.com database. The report width of pages: 350 Figures: 60 And Tables: 220 in it.  Global Next-Generation Sequencing (NGS) Market describes complete industry Outlook with in-depth analysis. This report also includes the complete analysis of each segment in terms of opportunity, market attractiveness index and growth rate, top players and new comers in industry, competitive landscape, sales, price, r...

Global Companion Diagnostic Markets Report 2021-2025: Level of Care, Immuno-oncology, Liability & Aging Population Driving Growth - Vimarsana News

Global Companion Diagnostic Markets Report 2021-2025: Level of Care, Immuno-oncology, Liability & Aging Population Driving Growth

Will Personalized Companion Diagnostics become the norm for diagnostics? Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market. Learn all about how diagnostic players are jockeying for position with their pha...